METHOTREXATE SODIUM INJECTION 25 MG
METHOTREXATE (METHOTREXATE SODIUM) : 25 MG · DIN 02099705 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is METHOTREXATE SODIUM INJECTION?
METHOTREXATE SODIUM INJECTION 25 MG contains METHOTREXATE (METHOTREXATE SODIUM) : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02099705, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRA-ARTERIAL ; INTRAMUSCULAR ; INTRATHECAL ; INTRAVENOUS ; INTRACEREBROVENTRICULAR administration. Health Canada currently lists it as marketed, status dated 31-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METHOTREXATE SODIUM INJECTION used for?
Neoplastic diseases (Choriocarcinoma, NHL, Breast, ALL, Head/Neck, Gastric, Bladder Cancer, Osteogenic sarcoma) and severe disabling psoriasis, psoriatic arthritis, or rheumatoid arthritis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is METHOTREXATE SODIUM INJECTION called?
The same molecule, METHOTREXATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| METOJECT PEN | Latin | Czechia |
| NORDIMET | Latin | Czechia |
| INJEXATE | Latin | Czechia |
| TREXAN NEO | Latin | Czechia |
| Trexject | Latin | Australia |
| DBL Methotrexate | Latin | Australia |
| INJEXATE AUTOINJEKTOR | Latin | Czechia |
| Metoject | Latin | Czechia, Saudi Arabia |
| FOXIEMO | Latin | Czechia |
| Chexate | Latin | Australia |
| Methoblastin | Latin | Australia |
| METHOTREXAT EBEWE | Latin | Czechia |
| Methotrexate Accord | Latin | Australia |
| METHOTREXATE BIODIM | Latin | Morocco |
| Methotrexate Ebewe | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02099705 |
|---|---|
| Brand name | METHOTREXATE SODIUM INJECTION |
| Generic / active ingredient | METHOTREXATE (METHOTREXATE SODIUM) : 25 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 25 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRA-ARTERIAL ; INTRAMUSCULAR ; INTRATHECAL ; INTRAVENOUS ; INTRACEREBROVENTRICULAR |
| Schedule | Prescription |
| ATC code | L01BA01 METHOTREXATE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Aug-2017 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02099705 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2099705 |
| Brand name | METHOTREXATE SODIUM INJECTION |
| Active ingredient / INN | METHOTREXATE (METHOTREXATE SODIUM) : 25 MG |
| ATC code | L01BA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Weekly dosing for RA/psoriasis (max 20-25mg/week). Neoplastic diseases: IV, IM, intra-arterial, intrathecal, or intracerebroventricular. High-dose regimens require leucovorin rescue and hydration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Section 11 was listed in TOC but text ends at Section 4.2).
How is it supplied?
Not explicitly detailed in provided text beyond 'vials' implied by 'Solution (Preservative-Free)'.
Which pack is which?
| Strength on the label | 25 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRA-ARTERIAL ; INTRAMUSCULAR ; INTRATHECAL ; INTRAVENOUS ; INTRACEREBROVENTRICULAR |
| Packaging as described in the monograph | Not explicitly detailed in provided text beyond 'vials' implied by 'Solution (Preservative-Free)'. |
| Storage | Not specified in the provided text (Section 11 was listed in TOC but text ends at Section 4.2). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; severe renal impairment; pregnancy (for psoriasis/RA); nursing mothers; alcoholism/chronic liver disease; immunodeficiency; pre-existing blood dyscrasias; nitrous oxide anesthesia.
Warnings and precautions
Use only by physicians experienced in antimetabolite therapy. Potential for serious toxic reactions, fetal death, and congenital anomalies. Monitor for myelosuppression and organ toxicity.
Is METHOTREXATE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BA01 METHOTREXATE. 20 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-METHOTREXATE | 2.5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02509067 |
| APO-METHOTREXATE | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02182963 |
| JAMP METHOTREXATE TABLETS | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02553740 |
| M-METHOTREXATE | 2.5 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02534916 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02464365 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02474735 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02474891 |
| METHOTREXATE INJECTION BP | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02327236 |
| METHOTREXATE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02182947 |
| METHOTREXATE INJECTION USP | 25 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02182955 |
Who else supplies METHOTREXATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHOTREXATE appears in 251 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does METHOTREXATE cost around the world?
METHOTREXATE is listed on 12 national price registers Nexara tracks, across 263 pack listings published on 11 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 9 | 77 | 03 Sep 2026 |
| Australia | ex-manufacturer | 7 | 36 | 08 Sep 2026 |
| Saudi Arabia | public | 19 | 33 | 01 Sep 2026 |
| United States | acquisition | 3 | 27 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 23 | 23 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 22 | 22 | 03 Sep 2026 |
| Morocco | PPV (public price) | 8 | 17 | 05 Sep 2026 |
| United Kingdom | hospital | 9 | 9 | 31 Aug 2026 |
| Luxembourg | reimbursement | 9 | 9 | 05 Sep 2026 |
| South Africa | single exit price | 7 | 7 | 01 Sep 2026 |
| Bahrain | retail (max) | 2 | 2 | 01 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.